Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes

Stopped Due to difficulty enrolling subjects whom had not meet the inclusion criteria

Conditions

• Graft Vs Host Disease

Interventions

• DRUG: DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use
• DEVICE: Regular dissolvable intracanalicular plug

Sponsor

Massachusetts Eye and Ear Infirmary

Collaborators

• [object Object]